Last update April 16, 2015

エトフェナマート

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a non-steroidal anti-inflammatory which is derived from Flufenamic acid, topically used but it can also be orally or intravenously administered.

At latest update relevant data related to breastfeeding were not found. However, we have information on its precursor the Flufenamic acid which is excreted into breast milk in non-significant amount and considered by the American Academy of Pediatrics as usual compatible with breastfeeding.

Absorption from skin to the plasma has been reported.

A high protein-binding capacity makes excretion into breast milk highly unlikely. However, it would be safer for both the mother and the infant the use of anti-inflammatory products with a proven safety while breastfeeding.

Avoid the use on the nipple or on extensive skin areas or long-term treatments to prevent systemic absorption.

Alternatives

  • Flufenamic Acid ( Safe. Compatible. Minimal risk for breastfeeding and infant.)
  • Ibuprofen ( Safe. Compatible. Minimal risk for breastfeeding and infant.)

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

エトフェナマート is also known as Etofenamate. Here it is a list of alternative known names::


Group

エトフェナマート belongs to this group or family:

Tradenames

Main tradenames from several countries containing エトフェナマート in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 21 (dermal) %
Molecular weight 369 daltons
Protein Binding 99 %
Tmax 2 - 5.6 hours
1.6 - 3.3 hours

References

  1. Bayer. Etofenamato. Ficha técnica. 2011 Full text (in our servers)
  2. Bender T, Bariska J, Rojkovich B, Bálint G. Etofenamate levels in human serum and synovial fluid following iontophoresis. Arzneimittelforschung. 2001 Abstract
  3. Herrera GL, Guevara LU, Torres GRA. Etofenamato: Características farmacologícas y clinicas de la formulación intramuscular. Rev Mex Anest 2001; 24 (4) 2001 Full text (link to original source) Full text (in our servers)
  4. Beckermann B, Bock E, Kamp R, Dell HD. [Plasma level studies in volunteers after intramuscular injection of various doses of etofenamate in an oily solution]. Arzneimittelforschung. 1990 Abstract
  5. Dell HD, Beckermann B, Fiedler J, Kamp R. [Renal elimination and metabolism of etofenamate in volunteers after administration of various doses]. Arzneimittelforschung. 1990 Abstract
  6. Dell HD, Fiedler J. [A test for excretion of etofenamate into milk]. Arch Pharm (Weinheim). 1983 Abstract

Total visits

2,275

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) of Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM